Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026.
Ginkgo Bioworks Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Ginkgo issued third-quarter fiscal 2026 results for the period ended September 30, 2026
- Results press release furnished as Exhibit 99.1, containing the substantive financial details
- Investor-relevant updates distributed through SEC filings, investor relations channels, website, conference calls and social media
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $27.7M, down 6% year over year but up from $20M in Q2, signaling sequential stabilization
- GAAP loss from continuing operations narrowed to $41.0M from $73.4M, while Adjusted EBITDA loss improved to $22M from $53M
- Cash, cash equivalents and marketable securities $285M at September 30, with Q3 cash burn of $27M
- First autonomous lab sale to Novo validates equipment commercialization, alongside ARPA-H subcontract worth up to $17.5M
- 2026 cash-burn outlook reaffirmed at $125M to $150M, keeping liquidity and execution against government and pharma demand central investor watchpoints
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ginkgo Bioworks Holdings, Inc. 8-K filings
Get the next DNA 8-K as it lands
Follow DNA for push alerts, or ask the research agent what this filing means.